

21.34

1. A humanized polynucleotide vector comprising:

a human derived promoter or mammalian homolog thereof which is functional in a target tissue or target cells, said promoter operably linked to a sequence acceptance site which directionally accepts cDNA target products from rtPCR cloning via unique sites within an interrupted palindrome recognition sequence for a restriction endonuclease, said vector lacking nucleic acid sequences encoding vector-derived polypeptides wherein, said vector lacks an antibiotic resistance encoding nucleic acid sequence.

2. The humanized polynucleotide vector according to claim 1 wherein the target cells are selected from the group consisting of myocytes and professional antigen presenting cells.

3. The humanized polynucleotide vector according to claim 1 or 2 wherein the target cells or target tissue are human.

4. The humanized polynucleotide vector according to claims 1-3 wherein the human derived promoter is a RANTES promoter or portion thereof.

5. The humanized polynucleotide vector according to claim 4 wherein the promoter has approximately 440 base pairs.

6. The humanized polynucleotide vector according to claims 4 or 5 wherein the portion corresponds to a region spanning the NCO site through the KpnI site of the genomic RANTES promoter

~~7. 8.~~ The humanized polynucleotide vector according to claims 1-5 or 6 further comprising an origin for replication and growth and a nucleic acid sequence which allows for selection of recombinant plasmids.

~~8. 9.~~ The humanized polynucleotide vector according to claim 8 wherein the origin for replication is colE1 or functional portion thereof.

03242202-110199

Sub
C1

Rule
1.126

Sub
C2

10-2-97

AR-34

WO98/06863

PCT/US97/14306

- 104/1 -

Sub
C2

66 F D T T " 20224260

~~9~~ 10. The humanized polynucleotide vector according to claim 8 wherein the origin for replication comprises a 635 base pair region of the colE1 origin of replication.

~~10~~ 11. The humanized polynucleotide vector according to claim 1 to 6 or 8-10 further comprising a human-derived 3' splice sequence and a human-derived poly A sequence, both sequences located downstream of the sequence acceptance site.

~~11~~ 12. The humanized polynucleotide vector according to claim 11 wherein the human derived 3' splice and poly A sequence are derived from human growth hormone.

~~12~~ 13. A polynucleotide vector according to claims 1-6 or 8-12 wherein a 5' sequence acceptance site reads on the positive strand as GCCACCATGGCC.

~~13~~ 14. A polynucleotide vector comprising SEQ ID No 16, SEQ ID No 27 or SEQ ID No 28.

~~14~~ 15. A polynucleotide vector contained within a host cell deposited with the ATCC under the ATCC designation 98400 or ATCC designation 98401.

~~15~~ 16. A polynucleotide vector according to claims 1-6 or 8-15 further comprising cDNA target products, and an optional internal ribosomal entry site, said cDNA target products integrated into said sequence acceptance site, said cDNA target products comprising a nucleotide sequence encoding at least one target antigen or antigenic epitope thereof alone or in combination with a nucleotide sequence encoding a cytokine or chemokine.

~~16~~ 17. A polynucleotide vector vaccine comprising a human derived promoter or mammalian homolog thereof which is functional in a mammalian target tissue or mammalian target cell, said promoter operably linked to a sequence

Sub
C2

acceptance site which directionally accepts cDNA target products from rtPCR cloning via unique sites within an interrupted palindrome recognition sequence for a restriction endonuclease, an optional internal ribosomal entry site, and cDNA target products, said cDNA target products integrated into said sequence acceptance site, said cDNA target products comprising a nucleotide sequence encoding at least one target antigen or antigenic epitope thereof, and said vector lacking nucleic acid sequences encoding vector-derived polypeptides wherein, said vector lacks an antibiotic resistance encoding nucleic acid sequence.

66TDT" 20224250

AMENDED SHEET

A2134

WO 98/06863

PCT/US97/14306

- 105/1-

~~18.~~ A polynucleotide vector vaccine according to claim 17 wherein the target antigen is a product of a tumor associated genetic derangement.

~~19.~~ A polynucleotide vector vaccine according to claim 17 wherein the target antigen is a tumor antigen, bacterial antigen, viral antigen, or parasitic antigen.

~~1920.~~ The polynucleotide vector vaccine according to claims 17 or 18, wherein the tumor antigen is p53, RB, ras, int-2, Hst, Trc17, BRCA-1, BRCA-2, MUC-1, HER-2/neu, truncated EGFRvIII, CEA, MyC, Myb, OB-1, OB-2, BCR/ABL, GIP, GSP, RET, ROS, FIS, SRC, TRC, WT1, DCC, NF1, FAP, MEN-1, ERB-B1 or combinations thereof.

~~2021.~~ A polynucleotide vector vaccine according to claim 17, 18, 19 or 20 further comprising an additional cDNA target product comprising a nucleic acid sequence encoding a cytokine or chemokine.

~~2122.~~ A polynucleotide vector vaccine according to claim 21 wherein the cytokine is selected from the group consisting of interleukin 2, interleukin 3, interleukin 4, interleukin 7, interleukin 8, interleukin 12, interleukin 15, GM-CSF, tumor necrosis factor, and interferon.

~~2223.~~ A polynucleotide vector vaccine according to claim 21 wherein the chemokine is selected from the group consisting of RANTES, MCP, MIP-1 α , MIP-1 β , defensins, IP-10 and combinations thereof.

~~2324.~~ A method for expressing at least one target antigen or antigenic epitope thereof in cells comprising:

introducing a humanized polynucleotide vector into said cells, under conditions for expression of the target antigen or antigenic epitope thereof, said vector comprising:

a human derived promoter or mammalian homolog thereof, which is functional in said cells, said promoter operably linked to a sequence acceptance site which directionally accepts cDNA target products from rPCR cloning via unique sites within an interrupted palindrome recognition sequence for a restriction endonuclease and,

Sub C2
cDNA target products, and an optional internal ribosomal entry site, said cDNA target products integrated into said sequence acceptance site, said cDNA target products comprising a nucleic acid sequence encoding at least one target antigen or antigenic epitope thereof, and said vector lacking nucleic acid sequences encoding vector-derived polypeptides, wherein said vector lacks an antibiotic resistance encoding nucleic acid sequence.

24/25. The method of claim 24 wherein the cells are selected from the group consisting of myocytes and professional antigen presenting cells.

25/26. The method of claim 24 wherein the target antigen is a tumor antigen bacterial antigen, viral antigen, or parasitic antigen.

26/27. The method of claim 26 wherein the tumor antigen is p53, RB, ras, int-2, Hst, Tre 17, BRCA-1, BRCA-2, MUC-1, HER-2/neu, truncated EGFRvIII, CEA, MyC, Myb, OB-1, OB-2, BCR/ABL, GIP, GSP, RET, ROS, FIS, SRC, TRC, WT1, DCC, NF1, FAB, MEN-1, ERB-B1 or combinations thereof.

27/28. A pharmaceutical composition comprising at least one polynucleotide vector according to claims 1-6 or 8-16 and a pharmaceutically acceptable carrier.

28/29. A pharmaceutical composition comprising the polynucleotide vector vaccine according to claims 17-22 or 23 and a pharmaceutically acceptable carrier.

29/30. A kit comprising the polynucleotide vector according to claims 1-6 or 8-16.

30/32. A kit comprising the polynucleotide vector vaccine according to claims 17-22 or 23.

31/33. A kit according to claim 32, further comprising an expression enhancing agent.

32/34. The kit according to claim 33 wherein the expression enhancing agent

Sub
C₂

is a mycotoxic agent.

~~33~~
~~35.~~ The kit according to claim 34 wherein the mycotoxic agent is bupivacaine-HCl and dextrose.

~~34~~
~~36.~~ A host cell comprising:
the polynucleotide vector of claim 17-22 or 23, wherein the host cell is capable of expressing the target antigen or antigenic epitope.

~~35~~
~~37.~~ The host cell according to claim 36 wherein the host cell is a myocyte or professional antigen presenting cell.

~~36~~
~~38.~~ A method of stimulating a specific immune response to at least one target antigen or antigenic epitope thereof in a mammal comprising: administration of an effective amount of a polynucleotide vector vaccine according to claim 17-22 or 23 into the mammal, said amount elicits the specific immune response to the target antigen or epitope thereof.

~~37~~
~~39.~~ The method according to claim 38, wherein a site of administration is muscle or skin.

~~38~~
~~40.~~ The method according to claim 38 further comprising administration of effective amount of an expression enhancing agent prior to administration of the polynucleotide vector vaccine.

~~39~~
~~41.~~ The method according to claim 40 wherein the expression enhancing agent is a mycotoxic agent.

~~40~~
~~42.~~ The method according to claim 41 wherein the mycotoxic agent is bupivacaine-HCl or dextrose.

~~41~~
~~43.~~ The method according to claim 38-41 or 42 wherein the target antigen is a tumor antigen, bacterial antigen, viral antigen or parasitic antigen.

Sub C2

~~42~~
~~44.~~ The method according to claim 43 wherein the tumor antigen is selected from the group consisting of P53, RB, ras, int-2, Hst, Tre 17, BRCA-1, BRCA-2, MUC-1, HER-2/neu, truncated EGFRvIII, CEA, MyC, Myb, OB-1, OB-2, BCR/ABL, GIP, GSP, RET, ROS, FIS, SRC, TRC, WT1, DCC, NF1, FAB, MEN-1, ERB-B1 and combinations thereof.

~~45.~~ The method according to claim 44 wherein the method generates antigen specific cytotoxic lymphocytes to the tumor antigen or antigenic epitopes thereof.

~~46.~~ A method of making a humanized polynucleotide vector comprising:
operably linking a human derived promoter or mammalian homolog thereof which is functional in a target tissue or target cells to a sequence acceptance site, said site directionally accepts cDNA target products from rtPCR cloning via unique sites within an interrupted palindrome recognition sequence for a restriction endonuclease, said vector lacking nucleic acid sequences encoding vector-derived polypeptides wherein, said vector lacks an antibiotic resistance encoding nucleic acid sequence.

~~47.~~ The method according to claim 46, wherein the human derived promoter is a RANTES promoter or portion thereof.

~~48.~~ A isolate antibody comprising an antibody elicited in response to immunization with the polynucleotide vector vaccine according to claim 17-22 or 23, said antibody is specific for the target antigen or antigenic epitope thereof expressed by the mammalian target tissue or mammalian target cell.

~~49.~~ The sequence acceptance site comprising nucleic acid sequences which accept cDNA target products from rtPCR cloning wherein the sequence acceptance site directionally accepts target sequence specific products from rtPCR cloning via unique sites within an interrupted palindrome recognition sequence for a restriction endonuclease.

~~50.~~ The sequence acceptance site according to claim 50 wherein the restriction endonuclease is Bgl I.

~~51.~~ The sequence acceptance site according to claim 50 or 51 wherein

a 5' acceptance site reads on the positive strand as GCCACCATGGCC.

⁵¹~~53~~. The sequence acceptance site according to claim ⁵² wherein a 3' acceptance site reads on the positive strand as GCCTTAAGGCC.

⁵¹~~54~~. The sequence acceptance site according to claim ⁵⁰ wherein the site comprises the nucleotide sequence as depicted in Figure 2.

~~65.~~ The humanized polynucleotide vector according to claim 8, wherein the

sub
C3
nucleic acid sequence which allows for selection is a suppressor tRNA gene, a synthetic SupF complementation tRNA gene, or functional derivatives thereof.

⁶²~~66~~. The humanized polynucleotide vector according to claim ⁶²~~65~~, wherein the nucleic acid sequence is selected from the group consisting of SupE, SupP, SupD, SupU, SupF, SupZ, glyT, glyU, SerP, psu⁺, psu⁺-C34, psu⁺AM and psu⁻OC.

⁶³~~67~~. A polynucleotide vector according to claims 1-6 or 8-12 wherein a 3' sequence acceptance site reads on the positive strand as GCCTTAAGGGC.

⁶⁴~~68~~. The humanized polynucleotide vector according to claims 1-6 or 8-13 wherein the sequence acceptance site comprises the nucleotide sequence as depicted in Figure 2.

⁶⁵~~69~~. The method according to any of claims 24 through 27 wherein the method is ex vivo.